Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer

Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer

Dysregulational EGFR, KRAS, and mTOR pathways cause metabolic reprogramming, leading to progression of gastric cancer. Afatinib (Afa) is a broad-spectrum tyrosine kinase inhibitor that reduces cancer growth by blocking the EGFR family. MicroRNA 125 (miR-125) reportedly diminishes EGFRs, glycolysis,...

Full description

Bibliographic Details
Main Authors: Yu-Li Lo, Tse-Yuan Wang, Chun-Jung Chen, Yih-Hsin Chang, Anya Maan-Yuh Lin
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
nanoparticle
tyrosine kinase inhibitor
microRNA
mitochondrial targeting
tumor metabolism reprogramming
mitochondrial dysfunction
Online Access:https://www.mdpi.com/1999-4923/14/9/1759

Internet

https://www.mdpi.com/1999-4923/14/9/1759

Similar Items